T3D.ASX: Appointment of Chief Executive Officer & Managing Director

Appointment of Chief Executive Officer & Managing Director

Stock	333D Ltd (T3D.ASX)
Release Time	6 Mar 2025, 4:17 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

333D Ltd Appoints New CEO & Managing Director

Key Points

Existing director Mr John Conidi appointed as CEO and Managing Director
Appointment effective from 1 March 2025
Substantial increase in revenue from medical digital asset strategy
Expects spike in radiology presentations due to increased GP bulk billing rates

Full Summary

333D Limited (ASX:T3D) has announced the appointment of existing director Mr John Conidi as the company's new Chief Executive Officer and Managing Director, effective 1 March 2025. Mr Conidi is a substantial shareholder of the company and has been instrumental in driving the company's digital asset management strategy. Over the last 12 months, the company has seen a substantial increase in revenue from its medical digital asset strategy. With Medicare being the focus of the current Federal election and both sides of Government committing an extra $8 billion to increase GP bulk billing rates, the company expects a substantial spike in radiology presentations, which is a boon for 333D and its partners. This justifies 333D's current strategy of investing in R&D to automate processes, increase efficiency, and lower the cost per presentation for its partners.

Outlook

The company expects a substantial spike in radiology presentations due to the increased GP bulk billing rates, which is a boon for 333D and its partners. The company's strategy of investing in R&D to automate processes, increase efficiency, and lower the cost per presentation for its partners is expected to pay off.